Ozone Therapy for Breast Cancer : An Integrative Literature Review
Breast cancer is the most prevalent form of cancer in women. Despite significant advances in conventional treatment, additional safer complementary treatment options are needed. Recently, ozone therapy has been considered as a type of medical adjunctive treatment that could inhibit cancer cell survival and reduce chemoresistance. However, only a few studies have been conducted on its use in breast cancer, and the optimal dosage and time of administration are unknown. Currently, preclinical studies suggest that ozone alone or in combination with chemotherapy is an effective method for inhibiting breast cancer cell growth. However, rather than investigating the effects of ozone as an antitumor therapy, current clinical trials have generally assessed its effect as an adjunctive therapy for reducing chemotherapy-induced side effects, increasing oxygen tension, normalizing blood flow, restoring blood lymphocytes more rapidly, and reducing fatigue symptoms. In this article, the use of ozone as a medical adjunctive treatment for breast cancer and its role in integrative therapy are summarized and discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Integrative cancer therapies - 23(2024) vom: 23. Jan., Seite 15347354241226667 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Yanchu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
66H7ZZK23N |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 26.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/15347354241226667 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367490226 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367490226 | ||
| 003 | DE-627 | ||
| 005 | 20240126232145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/15347354241226667 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM367490226 | ||
| 035 | |a (NLM)38258533 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Yanchu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ozone Therapy for Breast Cancer |b An Integrative Literature Review |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Breast cancer is the most prevalent form of cancer in women. Despite significant advances in conventional treatment, additional safer complementary treatment options are needed. Recently, ozone therapy has been considered as a type of medical adjunctive treatment that could inhibit cancer cell survival and reduce chemoresistance. However, only a few studies have been conducted on its use in breast cancer, and the optimal dosage and time of administration are unknown. Currently, preclinical studies suggest that ozone alone or in combination with chemotherapy is an effective method for inhibiting breast cancer cell growth. However, rather than investigating the effects of ozone as an antitumor therapy, current clinical trials have generally assessed its effect as an adjunctive therapy for reducing chemotherapy-induced side effects, increasing oxygen tension, normalizing blood flow, restoring blood lymphocytes more rapidly, and reducing fatigue symptoms. In this article, the use of ozone as a medical adjunctive treatment for breast cancer and its role in integrative therapy are summarized and discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a integrated treatment | |
| 650 | 4 | |a mechanisms | |
| 650 | 4 | |a ozone therapy | |
| 650 | 4 | |a safety | |
| 650 | 7 | |a Ozone |2 NLM | |
| 650 | 7 | |a 66H7ZZK23N |2 NLM | |
| 700 | 1 | |a Pu, Rong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Integrative cancer therapies |d 2002 |g 23(2024) vom: 23. Jan., Seite 15347354241226667 |w (DE-627)NLM126910472 |x 1552-695X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g day:23 |g month:01 |g pages:15347354241226667 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/15347354241226667 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |b 23 |c 01 |h 15347354241226667 | ||